Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery
Luis A Huerta Díaz, Brandon A Lopez Alanis, Luis F Zorrilla-Nuñez, Gerardo E Muñoz-Maldonado · 2026
Read Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery by Luis A Huerta Díaz, Brandon A Lopez Alanis, Luis F Zorrilla-Nuñez, Gerardo E Muñoz-Maldonado (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13518602.txt.
Description
Luis A Huerta Díaz and three colleagues review the return of weight after bariatric surgery in a 2026 article. Obesity behaves as a chronic, relapsing disease, and regain after surgery springs from hormone adaptation, behaviour, metabolic pushback, and anatomical change together. Re-operation was once the default answer, though it is technically harder and riskier than the first procedure.
A new drug wave changes the order of play. GLP-1 medicines deliver meaningful loss after surgery in trial after trial, above all when no fixable anatomical fault exists. The dual-action tirzepatide outperformed the older drugs and may suit selected patients best, with triple-action and oral agents behind it. The authors propose a step-wise path: check anatomy, rebuild lifestyle, add proven drugs, and reserve revision surgery for true anatomical failure. Modern medicines, they argue, can shrink, delay, or better target the return to theatre.
Catalog record
| CREATOR | Luis A Huerta Díaz, Brandon A Lopez Alanis, Luis F Zorrilla-Nuñez, Gerardo E Muñoz-Maldonado |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 60 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |